Source: BioSpace

Entasis Therapeutics: Entasis Therapeutics Completes Closing of Second Tranche of $35M Private Placement with Innoviva

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) ("Entasis"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the closing of the second tranche of the $35 million common stock and warrant investment by Innoviva, Inc. (NASDAQ: INVA) ("Innoviva"), a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited, under a

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Manos Perros's photo - President & CEO of Entasis Therapeutics Holdings, Inc.

President & CEO

Manos Perros

CEO Approval Rating

89/100

Entasis is a biotechnology company that develops and commercializes antibiotic therapies for the treatment of bacterial infections. Read more